![May 2021: Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis](https://icap.columbia.edu/wp-content/uploads/0-3-e1622128820264-1080x675.png)
Journal Club
![May 2021: Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis](https://icap.columbia.edu/wp-content/uploads/0-3-e1622128820264-1080x675.png)
![April 2021: IMPAACT 2010/VESTED trial evaluates the virological efficacy and safety of ART regimens containing DTG when started in pregnancy](https://icap.columbia.edu/wp-content/uploads/GettyImages-1208393752-1-e1619719000287-1080x675.jpg)
April 2021: IMPAACT 2010/VESTED trial evaluates the virological efficacy and safety of ART regimens containing DTG when started in pregnancy
Article: Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT...![March 2021: Expanded, population-level access to PrEP through the SEARCH study, with a flexible service delivery model, associated with lower HIV incidence among PrEP initiators in rural communities in Kenya and Uganda](https://icap.columbia.edu/wp-content/uploads/0-8-e1617138200583-1080x675.jpg)
March 2021: Expanded, population-level access to PrEP through the SEARCH study, with a flexible service delivery model, associated with lower HIV incidence among PrEP initiators in rural communities in Kenya and Uganda
Article: HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda. Published in: PLoS Med. 2021;18(2):e1003492 https://doi.org/10.1371/journal.pmed.1003492 Authors: Koss CA,...![February 2021: Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study](https://icap.columbia.edu/wp-content/uploads/ring_1200x900-100-1080x675.jpg)
February 2021: Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study
Article: Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study Published in: Lancet HIV. 2021;8(2):e87-e95 https://doi.org/10.1016/S2352-3018(20)30304-0 Authors: Baeten JM, Palanee-Phillips T,...![January 2021: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results](https://icap.columbia.edu/wp-content/uploads/april-may-2020-jc-header-1080x675.png)